drugset / Trial / NCT02264106

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

NCT02264106

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To assess the absorption of 30 mg Lefradafiban in two formulations, each under physiological conditions and with 40 mg Pantoprazole

Timeline

Start
1998-04
Primary completion
1998-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lefradafiban Small molecule 30 mg Oral
Subject Pantoprazole Other / unclassified 40 mg

Indications

No indication recorded.